Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax® from The Medicines...
On the afternoon of June 13, 2018, we received an update from the U.S. Food & Drug Administration (“FDA”) concerning our pending approval for Generic Advair Diskus® that FDA has identified...
Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Mylan, in recognition of its outstanding commitment to increasing...
Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila™ (pegfilgrastim-jmbd), a...
Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical...
Educational materials to help empower your customers.
What to know about our high quality generics.
Details about our brand name and generic medicines.
Resources that meet the specific needs of your institution.
Copyright © 2018 Mylan N.V. All Rights Reserved.
For U.S. Audiences Only
Please select one of our websites from the list below.
Mylan also is proud to do business in these locations.